Literature DB >> 23568245

Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.

Xiao Du1, Yu-Pei Zhao, Tai-Ping Zhang, Li Zhou, Ge Chen, Quan-Cai Cui, Jie Shi, Tian-Xiao Wang, Lei You, Hong Shu.   

Abstract

BACKGROUND: Pancreatic cancer (PC) carries frequent chemoresistance and extremely dismal prognosis. The underlying mechanisms remain to be further elucidated. We here report the role of Notch1 in gemcitabine resistance and its prognostic significance in PC.
METHODS: A small interfering RNA (siRNA) specifically targeting Notch1 was transiently transfected into three PC cell lines (AsPC-1, BxPC-3, and MIA PaCa-2), followed by examination of chemosensitivity to gemcitabine. On the other hand, Notch1 expression was evaluated immunohistochemically and correlated with clinicopathological and prognostic variables.
RESULTS: Successful knockdown of Notch1 by specific siRNA induced increased chemosensitivity to gemcitabine in all three cell lines. Immunohistochemical staining revealed that Notch1 was highly expressed in PC tissues (54.8 %), in contrast to that in para-tumor tissues (16.4 %). In addition, Notch1 positivity was significantly correlated with early-term metastasis and shortened overall survival. Multivariate Cox regression identified Notch1 as an independent prognostic factor.
CONCLUSIONS: Notch1 contributes to chemoresistance to gemcitabine, and serves as a significant indicator of unfavorable prognosis in PC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568245     DOI: 10.1007/s00268-013-2010-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  29 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  The Notch signaling pathway is related to neurovascular progression of pancreatic cancer.

Authors:  Peter Büchler; Amiq Gazdhar; Mario Schubert; Nathalia Giese; Howard A Reber; Oscar J Hines; Thomas Giese; Güralp O Ceyhan; Michael Müller; Markus W Büchler; Helmut Friess
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

3.  Pancreatic resection for M1 pancreatic ductal adenocarcinoma.

Authors:  Shailesh V Shrikhande; Jörg Kleeff; Carolin Reiser; Jürgen Weitz; Ulf Hinz; Irene Esposito; Jan Schmidt; Helmut Friess; Markus W Büchler
Journal:  Ann Surg Oncol       Date:  2006-10-25       Impact factor: 5.344

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 5.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.

Authors:  Naoko Takebe; Pamela J Harris; Ronald Q Warren; S Percy Ivy
Journal:  Nat Rev Clin Oncol       Date:  2010-12-14       Impact factor: 66.675

Review 6.  Notch signalling in solid tumours: a little bit of everything but not all the time.

Authors:  Prathibha Ranganathan; Kelly L Weaver; Anthony J Capobianco
Journal:  Nat Rev Cancer       Date:  2011-04-14       Impact factor: 60.716

7.  Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice.

Authors:  Kenji Kimura; Kennichi Satoh; Atsushi Kanno; Shin Hamada; Morihisa Hirota; Mareyuki Endoh; Atsushi Masamune; Tooru Shimosegawa
Journal:  Cancer Sci       Date:  2007-02       Impact factor: 6.716

Review 8.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

9.  Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles.

Authors:  Elodie Ristorcelli; Evelyne Beraud; Sylvie Mathieu; Dominique Lombardo; Alain Verine
Journal:  Int J Cancer       Date:  2009-09-01       Impact factor: 7.396

10.  Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia.

Authors:  Jean-Paul De La O; Lyska L Emerson; Jessica L Goodman; Scott C Froebe; Benjamin E Illum; Andrew B Curtis; L Charles Murtaugh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-21       Impact factor: 11.205

View more
  9 in total

1.  Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.

Authors:  Gang-Gang Mu; Ling-Li Zhang; Hong-Yan Li; Yan Liao; Hong-Gang Yu
Journal:  Dig Dis Sci       Date:  2014-10-26       Impact factor: 3.199

2.  Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.

Authors:  Selvi Kunnimalaiyaan; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  HPB (Oxford)       Date:  2015-07-06       Impact factor: 3.647

3.  Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells.

Authors:  Selvi Kunnimalaiyaan; Jose Trevino; Susan Tsai; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  Mol Cancer Ther       Date:  2015-04-17       Impact factor: 6.261

4.  The Expression of Notch 1 and Notch 3 in Gallbladder Cancer and Their Clinicopathological Significance.

Authors:  Luyao Liu; Zhu-Lin Yang; Chunwei Wang; Xiongying Miao; Zhiyu Liu; Daiqiang Li; Qiong Zou; Jinghe Li; Lufeng Liang; Guixiang Zeng; Senlin Chen
Journal:  Pathol Oncol Res       Date:  2015-12-03       Impact factor: 3.201

Review 5.  Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology.

Authors:  Chiara Bazzichetto; Claudio Luchini; Fabiana Conciatori; Vanja Vaccaro; Ilaria Di Cello; Paola Mattiolo; Italia Falcone; Gianluigi Ferretti; Aldo Scarpa; Francesco Cognetti; Michele Milella
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

6.  DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.

Authors:  A Drouillard; F Puleo; J B Bachet; S Ouazzani; A Calomme; P Demetter; G Verset; J L Van Laethem; R Maréchal
Journal:  Br J Cancer       Date:  2016-10-18       Impact factor: 7.640

7.  Identification of potential prognostic ceRNA module biomarkers in patients with pancreatic adenocarcinoma.

Authors:  Lili Zhao; Bingrong Liu
Journal:  Oncotarget       Date:  2017-10-10

8.  Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.

Authors:  Zhengle Zhang; Han Han; Yuping Rong; Kongfan Zhu; Zhongchao Zhu; Zhigang Tang; Chenglong Xiong; Jing Tao
Journal:  J Exp Clin Cancer Res       Date:  2018-11-28

9.  Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer.

Authors:  Jiewei Lin; Zhiwei Xu; Junjie Xie; Xiaxing Deng; Lingxi Jiang; Hao Chen; Chenghong Peng; Hongwei Li; Jiaqiang Zhang; Baiyong Shen
Journal:  Cell Death Dis       Date:  2021-08-02       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.